| Pamela L Vincent, MD | |
|
3152 N University Ave, Suite 220, Provo, UT 84604-4729 | |
| (801) 229-1014 | |
| (801) 229-1067 |
| Full Name | Pamela L Vincent |
|---|---|
| Gender | Female |
| Speciality | Addiction Medicine |
| Experience | 38 Years |
| Location | 3152 N University Ave, Provo, Utah |
| Accepts Medicare Assignments | May be. She may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1376544874 | NPI | - | NPPES |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Bright Heart Health Medical Group A Medical Corporation | 2264775790 | 13 |
| Bright Heart Health Inc | 5597026310 | 15 |
News Archive
BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products today announced results of the pivotal CORD I Phase III clinical trial of XIAFLEX (collagenase clostridium histolyticum), a novel, first-in-class biologic for the nonsurgical treatment of Dupuytren's disease, was published in today's edition of the New England Journal of Medicine.
Researchers have shown that early dementia signs could be detected by a simple short scan of the individual's neck. The actual dementia symptoms could be seen up to 10 years after these signs are visible on the scans they add. If proven robust for all cases, this test could soon become routine for screening middle aged individuals and classifying them as high risk for dementia later in life.
A new study released Monday, Dec. 14, in Washington, D.C., criticizes the nation's food and beverage industry for failing to shift their marketing efforts aimed at children. The report said television advertising continues to contribute to epidemic levels of obesity, despite industry promises of reform.
In a significant step toward growing replacement kidneys, researchers at the University of Virginia School of Medicine have identified the cells that give rise to the blood vessels within the kidney. It's a discovery of critical importance, as efforts to grow kidneys have long been frustrated by the inability to create the vasculature necessary for a functional organ.
For the 250,000 Canadians living with type 1 diabetes, the days of desperately trying to keep their blood sugar stable are coming to an end.
› Verified 8 days ago
| Entity Name | Bright Heart Health Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447643853 PECOS PAC ID: 5597026310 Enrollment ID: O20180219001099 |
News Archive
BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products today announced results of the pivotal CORD I Phase III clinical trial of XIAFLEX (collagenase clostridium histolyticum), a novel, first-in-class biologic for the nonsurgical treatment of Dupuytren's disease, was published in today's edition of the New England Journal of Medicine.
Researchers have shown that early dementia signs could be detected by a simple short scan of the individual's neck. The actual dementia symptoms could be seen up to 10 years after these signs are visible on the scans they add. If proven robust for all cases, this test could soon become routine for screening middle aged individuals and classifying them as high risk for dementia later in life.
A new study released Monday, Dec. 14, in Washington, D.C., criticizes the nation's food and beverage industry for failing to shift their marketing efforts aimed at children. The report said television advertising continues to contribute to epidemic levels of obesity, despite industry promises of reform.
In a significant step toward growing replacement kidneys, researchers at the University of Virginia School of Medicine have identified the cells that give rise to the blood vessels within the kidney. It's a discovery of critical importance, as efforts to grow kidneys have long been frustrated by the inability to create the vasculature necessary for a functional organ.
For the 250,000 Canadians living with type 1 diabetes, the days of desperately trying to keep their blood sugar stable are coming to an end.
› Verified 8 days ago
| Entity Name | Bright Heart Health Medical Group A Medical Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427569037 PECOS PAC ID: 2264775790 Enrollment ID: O20190523001697 |
News Archive
BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products today announced results of the pivotal CORD I Phase III clinical trial of XIAFLEX (collagenase clostridium histolyticum), a novel, first-in-class biologic for the nonsurgical treatment of Dupuytren's disease, was published in today's edition of the New England Journal of Medicine.
Researchers have shown that early dementia signs could be detected by a simple short scan of the individual's neck. The actual dementia symptoms could be seen up to 10 years after these signs are visible on the scans they add. If proven robust for all cases, this test could soon become routine for screening middle aged individuals and classifying them as high risk for dementia later in life.
A new study released Monday, Dec. 14, in Washington, D.C., criticizes the nation's food and beverage industry for failing to shift their marketing efforts aimed at children. The report said television advertising continues to contribute to epidemic levels of obesity, despite industry promises of reform.
In a significant step toward growing replacement kidneys, researchers at the University of Virginia School of Medicine have identified the cells that give rise to the blood vessels within the kidney. It's a discovery of critical importance, as efforts to grow kidneys have long been frustrated by the inability to create the vasculature necessary for a functional organ.
For the 250,000 Canadians living with type 1 diabetes, the days of desperately trying to keep their blood sugar stable are coming to an end.
› Verified 8 days ago
| Entity Name | Korean Community Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861525602 PECOS PAC ID: 0446495105 Enrollment ID: O20211118000437 |
News Archive
BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products today announced results of the pivotal CORD I Phase III clinical trial of XIAFLEX (collagenase clostridium histolyticum), a novel, first-in-class biologic for the nonsurgical treatment of Dupuytren's disease, was published in today's edition of the New England Journal of Medicine.
Researchers have shown that early dementia signs could be detected by a simple short scan of the individual's neck. The actual dementia symptoms could be seen up to 10 years after these signs are visible on the scans they add. If proven robust for all cases, this test could soon become routine for screening middle aged individuals and classifying them as high risk for dementia later in life.
A new study released Monday, Dec. 14, in Washington, D.C., criticizes the nation's food and beverage industry for failing to shift their marketing efforts aimed at children. The report said television advertising continues to contribute to epidemic levels of obesity, despite industry promises of reform.
In a significant step toward growing replacement kidneys, researchers at the University of Virginia School of Medicine have identified the cells that give rise to the blood vessels within the kidney. It's a discovery of critical importance, as efforts to grow kidneys have long been frustrated by the inability to create the vasculature necessary for a functional organ.
For the 250,000 Canadians living with type 1 diabetes, the days of desperately trying to keep their blood sugar stable are coming to an end.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Pamela L Vincent, MD 3214 N University Ave # 224, Provo, UT 84604-4405 Ph: (801) 885-2303 | Pamela L Vincent, MD 3152 N University Ave, Suite 220, Provo, UT 84604-4729 Ph: (801) 229-1014 |
News Archive
BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products today announced results of the pivotal CORD I Phase III clinical trial of XIAFLEX (collagenase clostridium histolyticum), a novel, first-in-class biologic for the nonsurgical treatment of Dupuytren's disease, was published in today's edition of the New England Journal of Medicine.
Researchers have shown that early dementia signs could be detected by a simple short scan of the individual's neck. The actual dementia symptoms could be seen up to 10 years after these signs are visible on the scans they add. If proven robust for all cases, this test could soon become routine for screening middle aged individuals and classifying them as high risk for dementia later in life.
A new study released Monday, Dec. 14, in Washington, D.C., criticizes the nation's food and beverage industry for failing to shift their marketing efforts aimed at children. The report said television advertising continues to contribute to epidemic levels of obesity, despite industry promises of reform.
In a significant step toward growing replacement kidneys, researchers at the University of Virginia School of Medicine have identified the cells that give rise to the blood vessels within the kidney. It's a discovery of critical importance, as efforts to grow kidneys have long been frustrated by the inability to create the vasculature necessary for a functional organ.
For the 250,000 Canadians living with type 1 diabetes, the days of desperately trying to keep their blood sugar stable are coming to an end.
› Verified 8 days ago
Edward Leslie Kelly, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1300 E Center St, Provo, UT 84606 Phone: 801-344-4400 Fax: 801-344-4225 | |
Brent L Griffin, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1034 N 500 W, Provo, UT 84604 Phone: 801-357-4542 | |
Aaron William Sanders, DO Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 395 W Cougar Blvd Ste 601, Provo, UT 84604 Phone: 801-357-7525 | |
Sam J Coates, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1034 N 500 W, Provo, UT 84604 Phone: 801-357-4542 | |
Dr. Rodney A Cheal, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1300 E Center St, Provo, UT 84606 Phone: 801-344-4400 | |
Ms. Madhumathy Gundlapalli, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1300 E Center St, Provo, UT 84606 Phone: 801-344-4400 | |
Dr. Stephen Peters, PSYD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1157 N 300 W, Provo, UT 84604 Phone: 801-357-1200 |